Sinopharm, Sinopharm Vaccine, Advisory Group, Sinopharm, Coronavirus Vaccines, Vaccine Supply, Serum Institute Of India, Vaccine Technology, Emergency, The World Health Organization, Vaccines

Sinopharm, Sinopharm Vaccine

WHO panel OKs emergency use of China's Sinopharm vaccine

WHO panel OKs emergency use of China's Sinopharm vaccine

7/5/2021 7:47:00 PM

WHO panel OKs emergency use of China's Sinopharm vaccine

The World Health Organization gave emergency use authorization Friday to a COVID-19 vaccine manufactured by China's Sinopharm , potentially paving the way for millions of the doses to reach needy countries through a U.N.-backed program rolling out coronavirus vaccines . The decision by a WHO technical advisory group — a first for a Chinese vaccine — opens the possibility that Sinopharm 's offering could be included in the U.N.-backed COVAX program in coming weeks or months and distributed through UNICEF and the WHO’s Americas regional office. Aside from efficacy numbers, the Chinese manufacturer has released very little public data about its two vaccines — one developed by its Beijing Institute of Biological Products and the other by the Wuhan Institute of Biological Products.

AdStreamen Sie Netflix or Pay TV channels such as SKY, DAZN, Maxdome, beliebigen Filme oder Fernsehsendungen auf Ihren Großbildschirm.South China Morning PostChina hopeful EU investment deal can be ratified despite growing doubts over its futureChina says it hopes to see its investment agreement with the European Union ratified soon amid intense speculation that the EU may abandon the deal. An EU spokeswoman on Tuesday denied reports it had suspended efforts to ratify the deal signed with China but warned the ratification process “cannot be separated from the evolving dynamics of the wider EU-China relationship”. After the Comprehensive Agreement on Investment (CAI) was signed last year, relations between China and the EU have nosedived over human rights concerns in Xinjiang. In March, the EU joined the United States, Britain and Canada in imposing sanctions on Chinese officials for human rights abuses in Xinjiang. Beijing has retaliated with sanctions on European officials and academics, hitting the chances of the European Parliament ratifying the deal.Do you have questions about the biggest topics and trends from around the world? Get the answers with SCMP Knowledge, our new platform of curated content with explainers, FAQs, analyses and infographics brought to you by our award-winning team. China’s foreign ministry spokesman Wang Wenbin said on Thursday that Beijing wanted to keep up communications with the EU to ensure the deal was ratified as soon as possible. “The nature of the China-EU Comprehensive Agreement on Investment is mutually beneficial and serves the interest of China, the EU and the world,” Wang said at a regular press conference. “The Chinese side is willing to maintain communication with the EU side to push for the early ratification of the agreement, so as to benefit the people on both sides and to send a positive signal to the world about China and the EU upholding an open world economy.” What is the China-EU CAI and how is it different from a trade deal? Speculation emerged after the French news agency AFP quoted EU trade chief Valdis Dombrovskis as saying in an interview: “We have … for the moment suspended some efforts to raise political awareness on the part of the [European] Commission because it is clear that in the current situation, with the EU sanctions against China and the Chinese counter-sanctions, including against members of the European Parliament, the environment is not conducive to the ratification of the agreement.” In a written statement, the EU said: “The agreement needs to be now legally reviewed and translated before it can be presented for adoption and ratification. However, the ratification process of the [deal] cannot be separated from the evolving dynamics of the wider EU-China relationship.” It continued: “In this context, Chinese retaliatory sanctions targeting members of the European Parliament, and an entire parliamentary committee, are unacceptable and regrettable. The prospects for … ratification will depend on how the situation evolves.” The deal needs to be approved by the parliament but also the EU Council, which is made up of all 27 heads of government, before it can become law. China hits out as G7 slams Beijing over human rights, backs Taiwan Also on Thursday, Wang said the EU should not put up new trade barriers. It follows the EU’s proposed new rules – seen as targeting China – preventing subsidised firms devouring strategic European assets. “The EU … is also a beneficiary of free trade. We hope the EU side can continue to push for trade and investment liberalisation, reduce market barriers, especially avoid creating new barriers, and to provide an open, transparent, and non-discriminatory market environment for Chinese companies in Europe,” he said. The EU plan was announced on Wednesday alongside an updated industrial policy that was also partly aimed at countering China’s influence on the European economy. The draft proposals on subsidies, which require approval by the EU’s 27 member states, would make it more difficult for Chinese and other foreign firms to buy EU businesses or assets or bid for public contracts if they recipients of state subsidies.More from South China Morning Post:China hits out as G7 slams Beijing over human rights, backs TaiwanEU moves to curtail subsidised firms in veiled swipe at ChinaEU regulator starts review of China’s Sinovac vaccineWhat is going on in Xinjiang and who are the Uygur Muslims?EU aims to cut reliance on China for chips and pharmaceutical materialsThis article China hopeful EU investment deal can be ratified despite growing doubts over its future first appeared on South China Morning PostFor the latest news from the South China Morning Post download our mobile app. Copyright 2021.

China says radiation levels normal at Taishan nuclear plant Singaporeans should band together to clean up housing estates regularly amid shortage of cleaners Bukit Merah View market closure extended to June 26 after 9 more Covid-19 cases detected; cluster grows to 25

a day agoSPH CEO Ng Yat Chung 'takes umbrage' at reporter's 'editorial integrity' questionSingapore Press Holdings chief executive officer Ng Yat Chung took offence to a reporter's question about SPH's goal of "editorial integrity" at a news conference on 6 May to announce plans to spin off the conglomerate's ailing media business.

a day agoSouth China Morning PostHang Seng Bank’s chief executive to take three-month leave of absence as she recovers from medical conditionHang Seng Bank’s vice-chairman and chief executive officer Louisa Cheang Wai-wan will take a three-month leave of absence as she recovers from a medical condition first disclosed last year, according to a statement by the lender. Margaret Kwan Wing Han, executive director and the head of Hang Seng’s wealth and personal banking business, will serve as acting CEO during her absence, the bank said in a stock exchange filing. Shares of Hang Seng Bank declined by as much as 1 per cent amid an advancing market in Hong Kong. The bank, which is 62.14 per cent owned by HSBC, the biggest of Hong Kong’s currency-issuing lenders, announced Cheang was undergoing treatment for a “recently diagnosed medical condition” last July, without elaborating.Do you have questions about the biggest topics and trends from around the world? Get the answers with SCMP Knowledge, our new platform of curated content with explainers, FAQs, analyses and infographics brought to you by our award-winning team. Hang Seng did not disclose further details of her condition at the time, but said Cheang was able to continue her duties. The bank said at the time that her condition would not affect its strategic or development plans. People familiar with the situation previously said that her illness was not Covid-19 and she was not expected to take a lengthy sick leave. Cheang, a former HSBC executive, has served as Hang Seng’s vice-chairman and CEO since July 2017. She took the top job after the retirement of Rose Lee Wai-mun. Before joining Hang Seng she was group general manager and group head of retail banking at HSBC from 2014. She first joined HSBC in 1999 in its credit card department. Cheang’s leave of absence comes just weeks before independent director Irene Lee Yun Lien is expected to become the bank’s first woman to serve as chairman, replacing Raymond Ch’ien Kuo Fung, who is retiring after 13 years to devote time to his other commitments and interests. Lee’s appointment is expected to happen at the bank’s annual meeting on May 26. It also comes just months after Hang Seng reported a 33 per cent drop in profit to HK$16.7 billion in 2020, as the coronavirus pandemic weighed on investments and spending activity in Hong Kong, cutting into transaction volumes by its commercial and retail customers. The city’s economy rebounded sharply in the first quarter, growing by 7.8 per cent after reporting its worst contraction on record in 2020. Hong Kong’s lenders are also dealing with a period of historically low interest rates, which has weighed on revenue from traditional lending products tied to interest rates. Kwan, the acting CEO, has been with Hang Seng since 1995, joining from Standard Chartered Bank. She previously served as head of consumer assets, head of unsecured loans and senior marketing, as well as a stint as business development manager for unsecured lending.This article Hang Seng Bank’s chief executive to take three-month leave of absence as she recovers from medical condition first appeared on South China Morning PostFor the latest news from the South China Morning Post download our mobile app. Copyright 2021. headtopics.com

Read more: Yahoo Singapore »

Police arrest man seen naked in public in viral videos; 24-year-old to be charged on June 12

WHO gives emergency approval to Sinopharm, first Chinese COVID-19 vaccineGENEVA: The World Health Organization announced on Friday (May 7) it had approved a COVID-19 vaccine from China's state-owned drugmaker Sinopharm ...

Philippines' Duterte apologises for taking unapproved China jab'Don't follow my footsteps. It's dangerous because there are no studies, it might not be good for the body,' said Duterte.

US FDA to hold advisory panel meeting on use of COVID-19 vaccines in childrenThe US Food and Drug Administration said on Monday (May 10) it will hold a meeting of its independent panel of advisers on June 10 to discuss the ...

UK says people under 40 should be offered alternative to AstraZeneca vaccineBritain's panel of vaccine advisers on Friday said that people under 40 should be offered an alternative to AstraZeneca's COVID-19 shot where ...

US CDC panel to vote on using Pfizer COVID-19 shot in adolescentsAn advisory panel to the U.S. Centers for Disease Control and Prevention (CDC) will meet on Wednesday to review data on the use of Pfizer Inc and ...